ORL : ce qui a changé en 2024 [ORL : what's new in 2024]

Details

Ressource 1Request a copy Under embargo until 22/07/2026.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_6EEEA3880D81
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
ORL : ce qui a changé en 2024 [ORL : what's new in 2024]
Journal
Revue medicale suisse
Author(s)
Anschuetz L., Fries S., Todic J., Glasson N., Salati V., Gorostidi F., Sandu K., Lambercy K., Simon C.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
22/01/2025
Peer-reviewed
Oui
Volume
21
Number
902
Pages
147-149
Language
french
Notes
Publication types: Journal Article ; English Abstract ; Review
Publication Status: ppublish
Abstract
This article highlights recent advancements in otorhinolaryngology. It reviews innovations in managing sudden sensory-neural hearing loss through low-dose glucocorticoid treatments and explores pediatric audiology breakthroughs, particularly gene therapy for DFNB9 deafness. In speech pathology and oncology, a new minimally invasive robotic surgical approach enhances organ preservation for head and neck cancers. Rhinology advancements include biological therapies for chronic rhinosinusitis with polyps. Together, these developments expand therapeutic options, significantly improving patient quality of life in the ORL field.
Keywords
Humans, Genetic Therapy/methods, Genetic Therapy/trends, Quality of Life, Glucocorticoids/administration & dosage, Glucocorticoids/therapeutic use
Pubmed
Create date
24/01/2025 14:43
Last modification date
25/01/2025 7:13
Usage data